IP Library Granted Patent US 8,080,661
Granted Patent B2
US 8,080,661 · App. 12/586,843 · Granted Dec 20, 2011

Processes for the synthesis of tertiary amines

Assignee: Mallinckrodt LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,661
App. No.
12/586,843
Granted
Dec 20, 2011
Kind
B2
Abstract

The invention provides processes for the preparation of morphinans having a tertiary amine. In particular, the present invention provides processes for the formation of tertiary amine alkaloids by direct N-alkylation of secondary amine alkaloids, the processes co-mediated by an alkylating agent and a protic solvent or a mixture of a protic solvent and an aprotic solvent.

Claims (37)

1. A process for the preparation of a compound comprising Formula (II) from a compound comprising Formula (I) according to the following reaction:

wherein:

the alkylating agent is selected from the group consisting of alkyl halide represented by the formula R 17 X, and dialkyl sulfate represented by the formula R 17 2 SO 4 , wherein R 17 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl, and X is selected from the group consisting of Cl, Br and I;

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, SH, —SR 1611 , —OR 1611 , and —NR 1611 R 1612 ; hydrocarbyl, and substituted hydrocarbyl;

R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a R 8b , R 9 , R 10a R 10b , R 15a R 15b , R 16a R 16b , and R 14 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, SH, —SR 1611 , —OR 1611 , and —NR 1611 R 1613 ; hydrocarbyl, and substituted hydrocarbyl, wherein any pair of R #a and R #b wherein # is any one of 5, 6, 7, 8, 9, 10, 15, 16, optionally together form a group selected from the group consisting of ═O, ═S, and ═NR 1613 ;

R 1611 , R 1612 and R 1613 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

provided that one or more of R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a R 8b , R 9a , R 10a R 10b , R 15a R 15b , R 16a R 16b , and R 14 may come together to form one or more carbocyclic or heterocyclic rings.

2. The process of claim 1 , wherein the alkylating agent is selected from the group consisting of an alkyl halide having from one to ten carbon atoms, and a substituted alkyl halide having from one to ten carbon atoms; and the protic solvent is selected from the group consisting of water, alcohol, inorganic acid and organic acid.

3. The process of claim 1 , further comprising conducting the reaction in the presence of an agent selected from the group consisting of a proton acceptor; an aprotic solvent; a metal halide represented by the formula MX n , wherein M is selected from the group consisting of Li, Na, K, Cs, Mg, Ca, and Ba, X is selected from the group consisting of Cl, Br and I, and n=1 or 2; and combinations thereof.

4. The process of claim 1 , wherein the mole-to-mole ratio of the alkylating agent to protic solvent to compound comprising Formula (I) is from about 1:0.2:1 to about 2:5:1; the reaction is conducted in the presence of a proton acceptor; and the reaction is conducted at a temperature ranging from about 30° C. to about 85° C.

5. The process of claim 1 , wherein the compounds comprising Formula (I) and (II) are (+) enantiomers, (−) enantiomers, and combinations of both; and the configuration of C-9, C-13, and C-14, respectively, in the compounds comprising Formula (I) and (II) is selected from the group consisting of RRR, RRS, RSR, RSS, SRR, SRS, SSR, and SSS, provided, however, that the C-15 and C-16 atoms are either both on the alpha face of the compound or the beta face of the compound.

6. The process of claim 1 , wherein the formation of compounds comprising tertiary amines at position C-17 and compounds alkylated at R 3 when it comprises oxygen together comprise less than 2% by weight of the total compounds formed by the reaction.

7. The process of claim 1 , wherein the yield of the compound comprising Formula (II) is greater than 90%.

8. A process for the preparation of a compound comprising Formula (IIa) from a compound comprising Formula (Ia) according to the following reaction:

wherein:

the alkylating agent is selected from the group consisting of alkyl halide represented by the formula R 17 X, and dialkyl sulfate represented by the formula R 17 2 SO 4 , wherein R 17 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl, and X is selected from the group consisting of Cl, Br and I;

A is a heteroatom selected from oxygen and sulfur;

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, SH, —SR 1611 , —OR 1611 , and —NR 1611 R 1612 ; hydrocarbyl, and substituted hydrocarbyl;

R 5 , R 6a , R 6b , R 7a , R 7b , R 8a R 8b , R 9 , R 10a R 10b , R 15a R 15b , R 16a R 16b , and R 14 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, SH, —SR 1611 , —OR 1611 , and —NR 1611 R 1613 ; hydrocarbyl, and substituted hydrocarbyl, wherein any pair of R #a and R #b wherein # is any one of 6, 7, 8, 9, 10, 15, 16, optionally together form a group selected from the group consisting of ═O, ═S, and ═NR 1613 ;

R 1611 , R 1612 and R 1613 are independently selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

provided that one or more of R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7a , R 7b , R 8a R 8b , R 9a , R 10a R 10b , R 15a R 15b , R 16a R 16b , and R 14 may come together to form one or more carbocyclic or heterocyclic rings.

9. The process of claim 8 , wherein the alkylating agent is selected from the group consisting an alkyl halide having from one to ten carbon atoms, and a substituted alkyl halide having from one to ten carbon atoms; and the protic solvent is selected from the group consisting of water, alcohol, inorganic acid and organic acid.

10. The process of claim 8 , further comprising conducting the reaction in the presence of an agent selected from the group consisting of a proton acceptor; an aprotic solvent; a metal halide represented by the formula MX n , wherein M is selected from the group consisting of Li, Na, K, Cs, Mg, Ca, and Ba, X is selected from the group consisting of Cl, Br and I, and n=1 or 2; and combinations thereof.

11. The process of claim 8 , wherein the mole-to-mole ratio of the alkylating agent to protic solvent to compound comprising Formula (Ia) is from about 1:0.2:1 to about 2:5:1; the reaction is conducted in the presence of a proton acceptor; and the reaction is conducted at a temperature ranging from about 30° C. to about 85° C.

12. The process of claim 8 , wherein the compounds comprising Formula (Ia) and (IIa) are (+) enantiomers; (−) enantiomers; and combinations of both; and the configuration of C-5, C-9, C-13, and C-14, respectively, in the compounds comprising Formula (Ia) and (IIa) is selected from the group consisting of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, and SSSS, provided, however, that the C-15 and C-16 atoms are either both on the alpha face of the compound or the beta face of the compound.

13. The process of claim 8 , wherein the formation of compounds comprising tertiary amines at position C-17 and compounds alkylated at R 3 when it comprises oxygen together comprise less than 2% by weight of the total compounds formed by the reaction.

14. The process of claim 8 , wherein the yield of the compound comprising Formula (IIa) is greater than 90%.

15. The process of claim 8 , wherein the process comprises the preparation of a compound comprising Formula (IIa-2) from a compound comprising Formula (Ia-1) according to the following reaction:

wherein the alkylating agent is selected from the group consisting an alkyl halide having from one to ten carbon atoms, and a substituted alkyl halide having from one to ten carbon atoms; and the protic solvent is selected from the group consisting of water, alcohol, inorganic acid and organic acid.

16. The process of claim 8 , wherein the process comprises the preparation of a compound comprising Formula (IIb-2) from a compound comprising Formula (Ib-1) according to the following reaction:

17. The process of claim 16 , wherein the compounds comprising Formula (Ib-1) and (IIb-2) are (+) enantiomers; and the formation of compounds comprising Formula (IIb-3) and (IIb-4) together comprise less than 2% by weight of the total compounds formed by the reaction:

18. The process of claim 16 , wherein the compounds comprising Formula (Ib-1) and (IIb-2) are (−) enantiomers; and the formation of compounds comprising Formula (IIb-5) and (IIb-6) together comprise less than 2% by weight of the total compounds formed by the reaction:

19. The process of claim 8 , wherein the process comprises the preparation of a compound comprising Formula (IIc-2) from a compound comprising Formula (Ic-1) according to the following reaction:

wherein the alkylating agent is selected from the group consisting an alkyl halide having from one to ten carbon atoms, and a substituted alkyl halide having from one to ten carbon atoms; and the protic solvent is selected from the group consisting of water, alcohol, inorganic acid and organic acid.

20. The process of claim 19 , wherein the formation of compounds comprising tertiary amines at position C-17 and compounds that are alkylated at position C-3 together comprise less than 2% by weight of the total compounds formed by the reaction.

21. The process of claim 8 , wherein the process comprises the preparation of a compound comprising Formula (IId-2) from a compound comprising Formula (Id-1) according to the following reaction:

22. The process of claim 21 , wherein the formation of compounds comprising tertiary amines at position C-17 and compounds that are alkylated at position C-3 together comprise less than 2% by weight of the total compounds formed by the reaction.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: WANG, PETER X.; JIANG, TAO; BERBERICH, DAVID W.
To: MALLINCKRODT INC.
Reel/Frame 023395/0075 →
Continuity (2)
Provisional Application 61194698 · Sep 30, 2008
Related Publication 20100081819A1 · Apr 1, 2010